The Therapeutic Human CD38 Antibody Daratumumab Improves the Anti-Myeloma Effect of Newly Emerging Multi-Drug Therapies

Blood Cancer Journal - United States
doi 10.1038/bcj.2011.42
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Daratumumab Induces CD38 Internalization and Impairs Myeloma Cell Adhesion

OncoImmunology
OncologyAllergyImmunology
2018English

The Mechanism of Action of the Anti-Cd38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

Therapeutic Advances in Hematology
Hematology
2019English

Mechanism of Action of a New Anti-Cd38 Antibody: Enhancing Myeloma Immunotherapy

Clinical Cancer Research
Cancer ResearchOncology
2019English

Daratumumab-Mediated Lysis of Primary Multiple Myeloma Cells Is Enhanced in Combination With the Human Anti-Kir Antibody IPH2102 and Lenalidomide

Haematologica
Hematology
2014English

Phase I Study of the Anti-FcRH5 Antibody-Drug Conjugate DFRF4539A in Relapsed or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates

Cancer Journal
Cancer ResearchOncology
2009English

CD38: From Positive to Negative Expression After Daratumumab Treatment

Cureus
2020English

Structural Characterization of a Potent Humanized Anti-Cd38 Antibody in Phase I

Acta Crystallographica Section A: Foundations and Advances
Materials ScienceCondensed Matter PhysicsTheoretical ChemistryBiochemistryStructural BiologyInorganic ChemistryPhysical
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy